Could Managing Inflammation Be the Key to Aging Well? Bayer and Hurdle Think So
Aging has long been accepted as an inevitable process, but what if we could measure the factors that accelerate it—and do something about them? That’s the idea behind InflammAge, a newly developed biomarker designed to measure systemic chronic inflammation, one of the key drivers of aging and age-related diseases.
The InflammAge biomarker is at the heart of a new partnership between Bayer and Hurdle, who have joined forces to advance precision health and help consumers take more control over their aging process. Chronic inflammation has been linked to conditions like cardiovascular disease, neurodegeneration, and metabolic disorders—yet until now, there hasn’t been an easy way for individuals to measure their own inflammatory status.
Aging and Inflammation: The Missing Link?
Research into aging has increasingly focused on inflammaging—a term used to describe the chronic, low-grade inflammation that builds up in the body over time and contributes to disease. While we typically think of inflammation as the body’s response to infection or injury, long-term, unresolved inflammation can silently damage cells and tissues, accelerating the aging process.
This is where InflammAge comes in. Developed using Hurdle’s AI-driven multi-omics biomarker discovery engine, it provides a saliva-based test that gives consumers direct insights into their inflammatory status. Unlike traditional diagnostic tests that require clinical visits and invasive procedures, InflammAge is designed to be accessible, making it easier for people to track how their lifestyle, diet, and environment may be influencing their health at a deeper level.
Bringing Precision Health to Everyday Consumers
The collaboration between Bayer and Hurdle is part of a broader trend in precision health, where advanced diagnostics—once limited to clinical research—are becoming available for everyday consumers. Instead of relying on generalized health advice, individuals can now get personalized data to help them make informed decisions about their health and aging process.
The move also reflects Bayer’s ongoing investment in consumer health innovations, aiming to bridge the gap between cutting-edge science and practical self-care solutions. By integrating Hurdle’s biomarker technology with Bayer’s reach in the healthcare market, the partnership could help reshape how people approach aging—not just as something to endure, but as a process that can be measured, understood, and managed.
What Comes Next?
InflammAge is just one step toward a more personalized approach to aging and disease prevention. As precision diagnostics continue to evolve, we may see more consumer-friendly tools that allow people to proactively manage their long-term health—rather than reacting to symptoms after the damage has been done.
Bayer and Hurdle’s partnership marks a shift in the way we think about aging. If inflammation is indeed one of the key drivers of age-related decline, then measuring and managing it could be one of the most powerful tools we have for living longer, healthier lives.
